Navigation Links
Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology

CAMPBELL, Calif., July 24, 2014 /PRNewswire/ -- Lazarus Effect, a medical device company focused on the development of novel interventional devices to facilitate removal of blood clots, announced today that the United States Patent and Trademark Office has issued a new patent (U.S. Patent Number 8,795,305) covering core technology behind the company's Lazarus CoverTM and ReCoverTM devices.

The Lazarus ReCover is a single-component stent-retriever (stentriever) with an integrated, novel, cover-based protection mechanism integrated onto the device. It is designed to cover and protect thrombus and to prevent loss of emboli during thrombectomy (clot removal) procedures. The Lazarus Cover is a unique, nitinol mesh cover that can be used with a variety of available retriever devices (including stentrievers) to protect the captured contents against loss during removal from the blood vessel.   

"This latest patent provides strong protection for Lazarus Effect technology that covers and protects captured content during retrieval procedures," said Martin Dieck, chairman and CEO, Lazarus Effect. "This patent will be a cornerstone in a series of Lazarus Effect patents relating to protected - and therefore improved - retrieval procedures."

The issued patent adds to the comprehensive patent portfolio Lazarus Effect has been building. The company currently has five issued US patents and numerous pending US and worldwide patent applications, including a patent issued in May 2014 covering additional technology related to the removal of clots in the brain. The Lazarus ReCover device has CE Mark for use in Europe. The Lazarus Cover device is pending CE Mark. Neither device is approved for sale in the United States.

About Lazarus Effect

Lazarus Effect is developing a complete portfolio of vascular-device products, including several to treat ischemic stroke, based on a patented, wire-frame technology platform.

Forward-looking Statements

Statements contained in this press release about Lazarus Effect, Inc. that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include changes in market or financial conditions, and other changes beyond the control of the Company. The Company specifically disclaims any obligation to update these forward-looking statements.

SOURCE Lazarus Effect
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Over Half of Audited Multiple Sclerosis Patients Currently Treated with Biogen Idecs Tecfidera Have Experienced Minor Side Effects Although Impact on Use Appears Muted
2. New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice
3. Clinical Trial Demonstrates That EarlySense May Be An Effective Indicator for Respiratory Pattern Recognition
4. New England Journal of Medicine Study Finds Upper-Airway Electronic Stimulation Effective for Obstructive Sleep Apnea
5. ObamaCare: Health Care Reform and its Effect on Sleep Apnea
6. Improving the Quality and Effectiveness of Marketing Services Groups in an Environment Characterized by Globalization and Shrinking Resources
7. New England Journal of Medicine releases study showing GSKs FluLaval Quadrivalent vaccine effective in preventing seasonal flu in children
8. Ibrutinib Data Published in The Lancet Oncology Suggest a Positive Effect in Previously Untreated Chronic Lymphocytic Leukemia Patients Over Age 65
9. Highland Instruments, Inc., Announces Presentation of "Effects of Electrosonic Stimulation on the Perception of Chronic Pain Due to Osteoarthritis of the Knee."
10. Frost & Sullivan Applauds Definiens Strong Technology Portfolio for the Effective Data Analysis of Histology Images
11. Ensuring Critical Leadership Messages are Effectively Communicated Across an Organization
Post Your Comments:
(Date:10/11/2017)... 11, 2017  BioPharmX Corporation (NYSE MKT: BPMX) researchers ... an innovative way to use nonlinear optical imaging to ... new drugs. ... will show how researchers from BioPharmX and the Wellman ... used a suite of imaging techniques in what is ...
(Date:10/11/2017)... , Oct. 11, 2017  True Health, ... has amplified its effort during National Breast Cancer ... hereditary cancer risks. ... Clinical Oncology calculated that more than 10 million ... inherited mutations in BRCA1 or BRCA2 and have not ...
(Date:10/10/2017)... received FDA 510(k) clearance in May 2017 for its highly anticipated ... for endoscopy environments. An innovative secondary monitor solution, ZeroWire Mobile ... the improvement of patient outcomes, procedural efficiency, and the lowering of ... ... By ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the ... – Miles by Moonlight to raise money for the American Heart Association Heart Walk. ... , Teams will work together to keep their treadmills moving for 5 hours. Treadmills ...
Breaking Medicine News(10 mins):